Efficacy of an OspA vaccine preparation for prevention of Lyme disease in New York State

Infection

Volumn 26, Issue 4, 1998, Pages 208-212

  Wormser, G P ^a   Nowakowski, J ^a   Nadelman, R B ^a   Schwartz, I ^a   McKenna, D ^a   Holmgren, D ^a   Aguero Rosenfeld, M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; MEMBRANE PROTEIN; VACCINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ERYTHEMA CHRONICUM MIGRANS; FEMALE; HIGH RISK POPULATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LYME DISEASE; MALE; MULTICENTER STUDY; NORMAL HUMAN;

EID: 0031813581     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02962365     Document Type: Article

References (28)

1. Steere, A. C.: Lyme disease. N. Engl. J. Med. 321 (1989) 586-596.
2. Fikrig, E., Barthold, S. W., Kantor, F. S., Flavell, R. A.: Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 250 (1990) 553-556.
3. Fikrig, E., Barthold, S. W., Kantor, F. S., Flavell, R. A.: Long-term protection of mice from Lyme disease by vaccination with OspA. Infect. Immun. 60 (1992) 773-777.
4. Chang, Y-F., Appel, M. J. G., Jacobson, R. H., Shin, S. J., Harpending, P., Straubinger, R., Patrican, L. A., Mohammed, H., Summers, B. A.: Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect. Immun. 63 (1995) 3543-3549.
5. Keller, D., Koster, F. T., Marks, D. H., Hosbach, P., Erdile, L. F., Mays, J. P.: Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA 271 (1994) 1764-1768.
6. Marks, D. H., Hosbach, P., Koster, F., Wormser, G., Bryant, G., Gwaltney, J., Froeschle, J., Erdile, L., Mays, J.: Clinical studies in humans of outer surface protein A (OspA) vaccine for Lyme disease. In: 6th International Conference on Lyme Borreliosis. Bologna. June 1994, abstr. no. 015.
7. Schoen, R. T., Meurice, F., Brunet, C. M., Cretella, S., Krause, D. S., Craft, J. E., Fikrig, E.: Safety and immunogenicity of an outer surface protein A vaccine in subjects with Lyme disease. J. Infect. Dis. 172 (1995) 1324-1329.
8. Sigal, L. H., Adler-Klein, D., Bryant, G., Doherty, T., Haselby, R., Hilton, E., Klempner, M. S., Kunkel, M., Malawista, S. E., Evans, J., Molloy, P., Sabetta, J., Seidner, A., Simon, H. J., Mays, J., Zahradnick, J. M., Marks, D.: Multicenter efficacy trial of a prophylactic recombinant Borrelia burgdorferi (Bb) outer surface protein A (OspA) vaccine for Lyme disease. IDSA 35th Annual Meeting. San Francisco. 13-16 September 1997. abstr. 422.
9. Centers for Disease Control and Prevention: Case definitions for infectious conditions under public health surveillance. MMWR 46 (1997) RR10: 20-21.
10. Schwartz, I., Wormser, G. P., Schwartz, J. J., Cooper, D., Weissensee, P., Gazumyan, A., Zimmermann, E., Goldberg, N. S., Bittker, S., Campbell, G. L., Pavia, C. S.: Diagnosis of early Lyme disease by polymerase chain reaction amplification or culture of skin biopsies from erythema migrans lesions. J. Clin. Microbiol. 30 (1992) 3082-3088.
11. Nadelman, R. B., Nowakowski, J., Forseter, G., Goldberg, N. S., Bittker, S., Cooper, D., Aguero-Rosenfeld, M., Wormser, G. P.: The clinical spectrum of early Lyme borreliosis in patients with culture confirmed erythema migrans. Am. J. Med. 100 (1996) 502-508.
12. Wormser, G. P., Forseter, G., Cooper, D., Nowakowski, J., Nadelman, R. B., Horowiti, H., Schwartz, I., Bowen, S. L., Campbell, G. L., Goldberg, N. S.: Use of a novel technique of eutaneous lavage for diagnosis of Lyme disease associated with erythema migrans. JAMA 268 (1992) 1311-1313.
13. Nadelman, R. B., Pavia, C. S., Magnarelli, C. A., Wormser, G. P.: Isolation of Borrelia burgdorferi from the blood of seven patients with Lyme disease. Am. J. Med. 88 (1990) 21-26.
14. Erdile, L. F., Brandt, M.-A., Warakomski, D. J., Westrack, G. J., Sadziene, A., Barbour, A. G., Mays, J. P.: Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect. Immun. 61 (1993) 81-90.
15. Mathiesen, D. A., Oliver, J. H. Jr., Kolbert, C. P., Tullson, E. D., Johnson, B. J. B., Campbell, G. L., Mitchell, P. D., Reed, K. D., Telford, S. R. III, Anderson, J. F., Lane, R. J., Persing, D. H.: Genetic heterogeneity of Borrelia burgdorferi in the United Stales. J. Infect. Dis. 175 (1997) 98-107.
16. Fikrig, E.,Telford, S. R. III, Wallich, R., Chen, M., Lobet, Y., Matuschka, F. R., Kimsey, R. B., Kantor, F. S., Barthold, S. W., Spielman, A., Flavell, R. A.: Vaccination against Lyme disease caused by diverse Borrelia burgdoreri. J. Exp. Med. 181 (1995) 215-221.
17. Padilla, M. L., Callister, S. M., Schell, R. F., Bryant, G. L., Jobe, D. A., Lovrich, S. D., DuChateau, B. K., Jensene, J. R.: Characterization of the protective borreliacidal antibody response in humans and hamsters alter vaccination with Borrelia burgdorferi outer surface protein A vaccine. J. Infect. Dis. 174 (1996) 739-746.
18. Wilske, B., Preac Mursic, V., Gobel, U. B., Graf, B., Jauris, S., Soutschek, E., Schwah, E., Zumstein, G.: An Osp A serotyping system for Borreiía b́urgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis. J. Clin. Microbiol. 31 (1993) 340-350.
19. ACP Task Force on Adult Immunization and Infectious Diseases Society of America: Guide for adult immunization. 3rd ed. American College of Physicians, Philadelphia 1994. p. 76.
20. Aguero-Rosenfeld, M. E., Horowitz, H. w., Wormser, G. P., McKenna, D. F., Nowakowski, J., Munoz, J., Dumler, J. S.: Human granulocytic ehrlichiosis (HGE): a case series from a single medical center in New York State. Ann. Intern. Med. 125 (1996) 904-908.
21. Wormser, G. P., Horowitz, H. W., Dumler, J. S., Schwartz, I., Aguero-Rosenfeld, M.: False-positive Lyme disease serology in human granulocytic ehrlichiosis. Lancet 347 (1996) 981-982.
22. Wormser, G. P., Horowitz, H. W., Nowakowski, J., McKenna, D., Dumler, J. S., Varde, S., Schwartz, I., Carbonaro, C., Aguero-Rosenfeld, M.: Positive Lyme disease serology in patients with clinical and laboratory evidence of human granulocytic chrlichiosis. Am. J. Clin. Pathol. 107 (1997) 142-147.
23. Lovrich, S. D., Callister, S. M., Lim, L. C. L., DuChateau, B. K., Schell, R. F.: Seroprotective groups of Lyme borreliosis spirochetes from North America and Europe. J. Infect. Dis. 170 (1994) 115-121.
24. Fikrig, E., Barthold, S. W., Persing, D. H., Sun, X., Kantor, F. S., Flavell, R. A.: Borrelia burgdorferi strain 25015: characterization of outer surface protein A and vaccination against infection. J. Immunol. 148 (1992) 2256-2260.
25. Wormser, G. P.: Prospects for a vaccine to prevent Lyme disease in humans. Clin. Infect. Dis. 21 (1995) 1267-1274.
26. Wilske, B., Barbour, A. G., Bergstrom, S., Burman, N., Restepo, B. I., Rosa, P. A., Schwan, T., Soutschek, E., Wallich, R.: Antigenic variation and strain heterogeneity in Borrrelia spp. Res. Microbiol. 143 (1992) 583-596.
27. Dykhuizen, D. E., Polin, D. S., Dunn, J. J., Wilske, B., Preac Mursic, V., Dattwyler, R. J., Luft, B. J.: Borrelia burgdorferi is clonal: implications for taxonomy and vaccine development. Proc. Natl. Acad. Sci. USA 90 (1993) 10163-10167.
28. Milch, L. J., Barbour, A. G.: Analysis of North American and European isolates of Borrelia burgdorferi with antiserum to a recombinant antigen. J. Infect, Dis. 160 (1989) 351-353.